Haoxi Health Technology Limited filings document foreign private issuer reporting for a China-based online marketing solutions provider with Class A ordinary shares listed on Nasdaq. Form 6-K reports furnish interim financial statements, management discussion and analysis, material-event disclosures and exhibits tied to the company’s operating results, liquidity and shareholder equity.
The company’s regulatory record also covers auditor changes, board composition, shareholder meeting notices and proxy materials, material agreements, shelf registration and at-the-market offering documents, private placement agreements, termination of financing arrangements and capital-structure disclosures involving ordinary shares and related securities.
Haoxi Health Technology Ltd. is offering 9,000,000 Class A ordinary shares at $0.25 per share and 16,999,998 pre-funded warrants (exercisable into up to 176,034,979 Class A shares), for gross proceeds of up to $6,455,799.51. The Pre-Funded Warrants have a $0.0026 exercise price and are exercisable upon issuance. The placement agent is Univest Securities, LLC. Pro forma net proceeds, assuming full exercise, are approximately $5.93 million. The offering is subject to PRC filing requirements under the CSRC Overseas Listing Trial Measures; the company says it will file with the CSRC within three working days after completion. The prospectus highlights risks tied to PRC regulatory developments, data/security rules, and potential HFCA Act delisting triggers tied to PCAOB inspection access. Key reported 2025 results: revenue $32.80 million and net income $3,876,680. Shares outstanding prior to offering: 58,753,028 Class A and 690,800 Class B (as of May 11, 2026).
Haoxi Health Technology Limited reported strong revenue growth but a steep increase in losses for the six months ended December 31, 2025. Net revenue rose to $33.83 million from $23.95 million, as the company expanded its online marketing services for healthcare advertisers and exited loss-making overseas operations, which helped lift gross margin to 4.72% from 2.01%.
Despite higher sales and improved margins, Haoxi recorded a net loss of $6.88 million, sharply wider than the $0.23 million loss a year earlier. The main drivers were a $6.02 million allowance for credit losses on prepaid advertising and third-party loans, and a $0.90 million impairment on digital intangible assets.
Operating cash outflow was $2.27 million, and the company invested $4.50 million in a convertible bond, partly funded by equity. Haoxi raised $4.93 million net from financing, including follow-on share offerings and warrant-related share issuances, ending the period with $6.80 million in cash and $15.96 million in shareholders’ equity. Management believes current liquidity covers at least 12 months of needs but acknowledges continued negative operating cash flows as it scales.
Haoxi Health Technology Limited reported a change in its independent auditor. The audit committee dismissed Wei, Wei & Co., LLP as the company’s independent registered public accounting firm, effective April 3, 2026, and appointed HCL, PLLC as the new independent auditor, also effective April 3, 2026.
The company states that during the fiscal years ended June 30, 2025 and 2024, and the subsequent interim period, the former auditor issued no adverse opinions or qualifications, had no disagreements on accounting or auditing matters, and no “reportable event” occurred. The company also confirms it did not consult HCL, PLLC on accounting or audit issues before the engagement.
Haoxi Health Technology Ltd director and Chief Operating Officer Xu Lei LX reported their holdings in the company. The Form 3 filing shows direct ownership of 214,400 Class A ordinary shares of Haoxi Health Technology Ltd, reflecting the executive’s initial reported equity position in the issuer.
Haoxi Health Technology Ltd director Su Changmao has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The filing does not report any stock transactions, share holdings, or derivative positions in the provided data for this reporting person.
Haoxi Health Technology Ltd director and CEO Fan Zhen has filed an initial statement of beneficial ownership. The filing reports direct ownership of 690,800 Class B ordinary shares, par value US$0.0025 each, as of March 18, 2026. The document does not show any new purchases or sales, but establishes Fan Zhen’s existing equity stake in the company.
Haoxi Health Technology Ltd officer Li Dongxue, the company’s Chief Financial Officer, filed an initial Form 3 reporting beneficial ownership. The data provided shows no reportable transactions, holdings, or derivative positions, indicating this is a baseline regulatory disclosure rather than a trading event.
Haoxi Health Technology Ltd director Hu Chuanjie has filed an initial Form 3 insider report. The filing identifies him as a director, not an officer or ten percent owner of Haoxi Health Technology Ltd. The data provided shows no reported transactions, derivative positions, or holdings entries at this time.
Haoxi Health Technology Ltd director Liu Jia has filed an initial insider ownership report on Form 3. The filing identifies Liu Jia as a director of the company and, in the provided data, shows no reported transactions, share purchases or sales, and no listed derivative positions.
Haoxi Health Technology Limited reported a change in its board of directors. On March 6, 2026, director Jianbing Zhang resigned from the board for personal reasons, and the company stated that his resignation did not involve any disagreement over operations, policies, or practices.
The board appointed Chuanjie Hu as a new director effective the same day and determined he meets the “independence” requirements of Nasdaq and Rule 10A-3. Mr. Hu will chair the nominating and corporate governance committee and serve on the compensation and audit committees, and will not receive compensation for his board service.